A phase 1/1b/2 study evaluating the safety tolerability pharmacokinetics pharmacodynamics and efficacy of AMG 193 alone and in combination with docetaxel in subjects with advanced MTAP-null solid tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Null Solid Tumors
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    To participate in the study the following conditions must be met:
    1. 1) The presence of CDKN2A (null) and/or MTAP (null) or the absence of MTAP expression in the tumor tissue
    2. 2) Metastatic or locally advanced solid tumor that cannot be treated with surgery and/or radiation with the goal of curing the cancer is eligible for the study
    3. 3) Are the age of 18 and have provided informed consent

You may not be eligible for this study if the following are true:

  • You will not be able to participate in the study if you have had:
    1. 1) Individuals who have compression of the spinal cord, active brain metastases (cancer that has spread to the brain), or leptomeningeal disease (cancer that has spread to the membranes surrounding the brain and spinal cord) caused by non-brain tumors
    2. 2) Presence of primary brain cancer
    3. 3) Presence of hematological malignancy or lymphoma

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.